- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03335423
Inter- and Intra-individual Variations in Metformin Pharmacokinetics - The Importance of Genes and Drug Interactions
The investigators aim to investigate the interindividual variation in metformin AUC in a large cohort of healthy volunteers after a single dose of metformin. Part 1 is driven by the hypothesis that metformin AUC and renal clearance exhibit significant interindividual variation. However this has never been documented in a large cohort of healthy volunteers.
The investigators aim to investigate the potential interaction between codeine and metformin in the intestine. The hypothesis underlying part 3 is that the increased risk of early discontinuation of metformin during co-administration with codeine is primarily due to local inhibition of OCT1 via codeine at the intestinal level.
Study Overview
Status
Conditions
Detailed Description
Part 1: The investigators intend to investigate the inter-individual variation in metformin Area Under Plasma Concentration Curve (AUC) following a single dose of oral metformin based on the plasma concentration of metformin after 3 and 10 hours and urine collection for 24 hours . Part 2: The investigators intend to contribute with DNA and metformin AUC determinations from subjects from part 1 to a major international study that aime to highlight the Genome Wide Association (GWA) between the entire genome and variations in metformin pharmacokinetics (AUC) in a large group of healthy subjects and patients. Part 3: The investigators aim to investigate the potential interaction between codeine and metformin in the intestine.
The investigators secondary objective in part 3 is to investigate if the plasma concentration of morphine increases when codeine and metformin are given together due to competitive inhibition of the Organic cation transporter 1 (OCT1) transport protein (in the liver). Furthermore, the investigators will measure lactate after metformin ingestion as a proxy for metformin's effect on the intestinal mucosa, both after oral and intravenous metformin
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Odense, Denmark, 5000
- The department of clinical pharmacy and pharmacology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria Part 1 (and 2): Men and women. Apparent good general health. eGFR, creatinine, Hba1c, must be within the reference range or clinically insignificantly differ from this. Written consent must be given. Age 18-65. BMI 18,5 - 29,9kg/m².
-
Exclusion Criteria part 1 (and 2): Daily consumption of medicine (prescription, over the counter and herbal medicines, dietary supplements (oral contraceptives and regular vitamin pills are accepted)). Alcohol abuse. Hypersensitivity for metformin. For women: positive pregnancy test and not using safe contraceptives for 24 hours after intake of metformin and breastfeeding.
Inclusion Criteria Part 3:Apparent good general health. eGFR, creatinine, Hba1c, glucose, ALAT and bilirubin must be within the reference range or clinically insignificantly differ from this. Written consent must be given. Age 18-30 . BMI 18,5 - 29,9kg/m².
Exclusion Criteria part 3: Daily consumption of medicine (prescription, over the counter and herbal medicines, dietary supplements (regular vitamin pills are accepted)). Alcohol abuse. Hypersensitivity for metformin, codeine or morphine. Genetically proven CYP2D6 slow or ultra-fast metabolizers. Genetically proven loss-of-function allele in OCT1
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oral Metformin
Oral metformin 1000mg will be given as a single dosis
|
The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases.
Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin.
Metformin was given alone and together with codeine to investigate a potential interaction between the drugs.
Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
|
Experimental: Intravenous metformin
Intravenous metformin 500mg will be injected as a single dosis
|
The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases.
Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin.
Metformin was given alone and together with codeine to investigate a potential interaction between the drugs.
Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
|
Experimental: Oral codeine and oral metformin
Codeine 25 mg will be given at 5 occasions with approximately 6 hours between each dosing.
The fifth and last dose will be given together with 1000 mg oral metformin
|
The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases.
Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin.
Metformin was given alone and together with codeine to investigate a potential interaction between the drugs.
Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
|
Experimental: Oral codeine and intravenous metformin
Codeine 25 mg will be given at 5 occasions with approximately 6 hours between each dosing.
The fifth and last dose will be given together with 500 mg metformin administrated as an injection.
|
The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases.
Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin.
Metformin was given alone and together with codeine to investigate a potential interaction between the drugs.
Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metformin AUC
Time Frame: blood samples will be collected after 3 and 10 hours for each subject (N=300) after oral metformin ingestion. Urine is collected for 24 hours.
|
Outcomes of part 1: Variation in metformin AUC in a large cohort of healthy volunteers after a single dose of metformin
|
blood samples will be collected after 3 and 10 hours for each subject (N=300) after oral metformin ingestion. Urine is collected for 24 hours.
|
Metformin AUC
Time Frame: Blood samples will be drawn in each of the 4 arms from ingestion of the drug/drugs and for 24 hours at suitable times. Urine is collected after ingestion of metformin for 24 hours.
|
Outcome of part 3; differences in AUC for metformin when given alone and together with codeine
|
Blood samples will be drawn in each of the 4 arms from ingestion of the drug/drugs and for 24 hours at suitable times. Urine is collected after ingestion of metformin for 24 hours.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Codeine AUC
Time Frame: Blood samples are collected for 6 hours after ingestion of the first codeine pill. Blood samples are also collected and measured for codeine, morphing, M3G,M6G for 6 hours after both oral and intravenous metformin
|
secondary outcome of part 3: differences in codeine AUC when codeine is given alone and together with metformin
|
Blood samples are collected for 6 hours after ingestion of the first codeine pill. Blood samples are also collected and measured for codeine, morphing, M3G,M6G for 6 hours after both oral and intravenous metformin
|
Lactate AUC
Time Frame: Blood samples for lactate will be drawn in each arm after metformin ingestion for 24 hours at suitable times
|
Secondary outcome of part 3: differences in lactate AUC after metformin is given orally and intravenously
|
Blood samples for lactate will be drawn in each arm after metformin ingestion for 24 hours at suitable times
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Kim Brøsen, professor, chief physcian, University of Southern Denmark
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1779
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metformin
-
Massachusetts General HospitalCompletedFasting Glucose | Metformin Response | Tryptophan Concentration | Metformin Concentration | Diet TolerabilityUnited States
-
Weill Medical College of Cornell UniversityAgency for Healthcare Research and Quality (AHRQ)CompletedTolerance | Metformin Adverse ReactionUnited States
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Subjects | Pharmacokinetics of Isavuconazole | Pharmacokinetics of MetforminUnited States
-
AstraZenecaCompletedBioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and MetforminUnited States
-
Tianjin Medical UniversityPeking University First Hospital; Peking Union Medical College Hospital; Zhongshan...RecruitingUveitis | Metformin | GlucocorticoidChina
-
Dexa Medica GroupCompletedMetformin XR BE Study in Healthy Volunteers With Single and Multiple DoseIndonesia
-
University of Southern DenmarkRegion of Southern DenmarkCompletedPharmacogenetics of MetforminDenmark
-
Xiang Guang-daUnknownAging | Metformin | Overweight SubjectsChina
-
West China HospitalNot yet recruitingKidney Transplantation | Metabolic Disorder | Metformin | Empagliflozin
-
HealthPartners InstituteAbbott Diabetes Care; International Diabetes Center at Park NicolletCompletedType 2 Diabetes | Currently Taking MetforminUnited States
Clinical Trials on Oral metformin
-
Weill Medical College of Cornell UniversityAgency for Healthcare Research and Quality (AHRQ)CompletedTolerance | Metformin Adverse ReactionUnited States
-
Woman'sPfizer; American Cancer Society, Inc.; Our Lady of the Lake Regional Medical...WithdrawnInsulin Resistance | Breast Cancer Stage | Racial BiasUnited States
-
Charles University, Czech RepublicCompleted
-
Lille Catholic UniversityCentre Hospitalier ArrasRecruitingObesity Without Type 2 Diabetes, With BMI>30France
-
Zealand University HospitalCompleted
-
Poznan University of Medical SciencesUniversity of California, San DiegoUnknown
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2 | Type 2 Diabetes MellitusMexico
-
Beni-Suef UniversityCompleted